Proactive Investors - Run By Investors For Investors

Allergy Therapeutics half yearly revenues grow amid market turmoil

Allergy Therapeutics said the global allergy treatment market had seen some “turmoil” that had affected the competitive market environment in Europe and the US.
Test tube graphics
Revenues grew 12%

Allergy Therapeutics plc (LON:AGY) saw revenues grow 12% to £48.5mln for the six months ended June.  

But a £16.2mln research and development spending drive meant losses widened to £13mln, resulting in losses per share of 2.29p.

Allergy Therapeutics said the global allergy treatment market had seen some “turmoil” affecting the competitive market environment in Europe and the US, but the group said it would likely see mid to long-term benefits in terms of its US market share.

The UK’s referendum vote had a short-term financial benefit for the group in terms of the weak pound against the euro, but the group said the long-term impact will depend on the final agreement between the UK and the rest of the EU.

The group had a self-confessed “mixed year” with a successful Phase II dose-ranging study for Pollinex Quattro Birch in Germany opening the way for a Phase III trial for the product in Europe, which is expected to start in early 2017.

The one-year follow-up study on Acarovac Plus concluded with patients reporting statistically significant improvements in satisfaction scores for effectiveness and convenience.

However, its Phase II Pollinex Quattro study in the US did not give conclusive evidence of an optimal dose regime.

“The allergy immunotherapy sector continues to undergo significant change and within this context our established and innovative product base continues to gain traction,” said chief executive Manuel Llobet.

The current allergy immunotherapy market is estimated to be US$2.1bn (£1.62bn) with the potential to reach US$3bn and is expected to grow at about 11% a year until 2020.

“We look forward to the future with confidence in continued growth given our strong and expanded European presence, future product development pipeline and geographic expansion opportunities,” added Llobet.

Shares fell 3% to 17.78p.

View full AGY profile View Profile

Allergy Therapeutics plc Timeline

Related Articles

cancer cell
January 31 2018
The highlights included successful US and European ovarian cancer studies that underlined the potential of the company’s Parsortix liquid biopsy system
man on a ventilator
January 24 2018
The share price, 280p a year ago, has tracked the progress the firm has made in the clinic with its lead product Traumakine
April 01 2018
The company is in the process of raising £5mln, with a possible further £1mln through a share issue at 52.5p

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use